Satellos Bioscience (MSLE) Income towards Parent Company (2025 - 2026)
Satellos Bioscience's (MSLE) quarterly Income towards Parent Company came in at -$9.7 million in Q1 2026, down 261.3% year-on-year from $6.0 million in Q1 2025, and down 261.3% on a QoQ basis from $6.0 million in Q1 2025.
Satellos Bioscience (MSLE) Income towards Parent Company (2025 - 2026) Analysis & Trends
Satellos Bioscience (MSLE) has 2 years of Income towards Parent Company data on file, last reported at -$9.7 million in Q1 2026.
- On a quarterly basis, Income towards Parent Company fell 261.3% year-over-year to -$9.7 million in Q1 2026; TTM through Mar 2026 was -$3.7 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$25.0 million, down 23.54% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$9.7 million, down from $6.0 million in the prior quarter.
- Over the last five years, Income towards Parent Company for MSLE reached as high as $6.0 million in Q1 2025 and fell as low as -$9.7 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Nanobiotix | 1,785.82 Bn | 1,785.76 Bn | - |
| 2 | Akari Therapeutics | 979.03 Bn | 979.03 Bn | - |
| 3 | BeOne Medicines | 473.13 Bn | 468.34 Bn | 1.35 Bn |
| 4 | Vertex Pharmaceuticals | 123.67 Bn | 116.43 Bn | 2.59 Bn |
| 5 | Regeneron Pharmaceuticals | 71.57 Bn | 62.81 Bn | 3.31 Bn |
| 6 | Belite Bio | 62.00 Bn | 62.00 Bn | - |
| 7 | Argenx Se | 54.61 Bn | 49.42 Bn | 1.41 Bn |
| 8 | Alnylam Pharmaceuticals | 37.99 Bn | 34.98 Bn | 959.66 Mn |
| 9 | Revolution Medicines | 36.09 Bn | 36.09 Bn | - |
| 10 | Satellos Bioscience | 180.72 Mn | 180.72 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.70 Mn |
| Mar 31, 2025 | 6.02 Mn |